Pinealon

A report involving locomotive workers described changes in biological-age and adaptation indicators after Pinealon use. The abstract does not provide the modern trial details needed to establish randomization, blinding, allocation concealment, validated clinical endpoints, complete adverse-event reporting, or durable benefit.

A 32-person study of Pinealon and Vesugen in participants with polymorbidity and organic brain syndrome reported changes in biological-age indicators, but also reported pro-oxidant activity and reduced circulating CD34-positive hematopoietic markers. The small sample, mixed compounds, unclear control methods, surrogate endpoints, and concerning laboratory signals prevent anti-aging, geroprotective, or safety claims, and prevent attribution to either compound alone.

A study of professional truck drivers and metal-worker controls reported the best psychoadaptive effect with combined Pinealon and Vesugen. Combination exposure, occupational confounding, unclear treatment allocation, and subjective endpoints prevent attribution of this result to either compound alone.

The study compared Pinealon and Cortexin in aged rats exposed to hypoxia or hypothermia and reported differences in behavior and oxidative-stress measures.

Pinealon improved selected cognitive and biochemical outcomes in rat offspring exposed to prenatal hyperhomocysteinemia.

The study included fluorescently labeled Pinealon (Glu-Asp-Arg) and reported cellular or nuclear penetration and interactions with nucleic-acid targets in vitro.

Pinealon was studied in experimental hypoxia models and showed neurobiological effects under those conditions. The findings are preclinical.

A biophysical study examined EDR-DNA interaction using molecular-docking and structural methods. This supports a mechanistic hypothesis only, not a validated human receptor, pharmacodynamic biomarker, or disease-modifying mechanism.

Laboratory studies reported that EDR/Pinealon reduced reactive-oxygen-species accumulation and necrotic cell death in selected neural and non-neural cell systems and altered ERK activation and cell-cycle behavior. These findings do not establish antioxidant therapy, neuroprotection, or clinical safety in humans, and cell-cycle effects create unresolved proliferative and oncologic questions.

Current Drugs@FDA name searches performed for this frozen package did not identify approved drug products under the names AHK-Cu, FOXO4-DRI, Pinealon, or Mechano Growth Factor. A negative name search does not exclude differently named products but establishes that no approval was identified under these research names.

Cardiogen, Cortagen, Pinealon, and Vesugen were not identified in FDA's current 503A nominated bulk-drug-substance category document, updated May 14, 2026. Absence from that document is not approval, a safety determination, or authorization to compound.

No modern registered interventional development program for Cardiogen, Cortagen, Pinealon, or Vesugen was identified in the reviewed ClinicalTrials.gov searches.

PubChem's Pinealon compound record establishes the identity of the synthetic tripeptide Glu-Asp-Arg (EDR). Used for identity verification only, not efficacy evidence.

Review discussing neuroepigenetic mechanisms proposed for ultrashort peptides, including EDR/Pinealon, in the context of gene-expression regulation.

The review discusses EDR/Pinealon mechanisms and summarizes preclinical and limited human observations. The evidence is not comparable to modern large randomized clinical trials.

The paper summarizes reported clinical use of peptide preparations, including Pinealon, in older adults, but provides limited modern trial detail in the English abstract.